We are live on ! Find out more
ACM

Aisling Capital Management Portfolio holdings

AUM $476M
1-Year Est. Return 128.63%
This Fund
S&P 500
This Quarter Est. Return
+20.52%
1 Year Est. Return
+128.63%
3 Year Est. Return
+700.94%
5 Year Est. Return
+846.44%
10 Year Est. Return
–
AUM
$288M
AUM Growth
+$6.62M
Cap. Flow
-$39.1M
Cap. Flow %
-13.54%
Top 10 Hldgs %
99.5%
Holding
15
New
–
Increased
1
Reduced
1
Closed
2

Top Buys

Rank Stock Value
1
CMPS
Compass Pathways
CMPS
+$898K

Top Sells

Rank Stock Value
1
VRNA
Verona Pharma
VRNA
+$29.9M
2
PSTX
Poseida Therapeutics, Inc. Common Stock
PSTX
+$10M
3
VIRX
Viracta Therapeutics, Inc. Common Stock
VIRX
+$46.2K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BBIO icon
1
BridgeBio Pharma
BBIO
$15.7B
$210M 72.72%
6,068,125
– –
VRNA
2
DELISTED
Verona Pharma
VRNA
$39.1M 13.54%
615,352
-500,000
-45% -$29.9M
SNDX icon
3
Syndax Pharmaceuticals
SNDX
$1.69B
$12.6M 4.36%
1,025,000
– –
BCAX
4
Bicara Therapeutics
BCAX
$1.78B
$7.41M 2.57%
568,919
– –
GLUE icon
5
Monte Rosa Therapeutics
GLUE
$1.4B
$6.83M 2.37%
1,472,331
– –
NUVB icon
6
Nuvation Bio
NUVB
$2.2B
$4.47M 1.55%
2,541,009
– –
CMPS
7
Compass Pathways
CMPS
$1.53B
$3.43M 1.19%
1,198,418
+233,918
+24% +$898K
BMEA icon
8
Biomea Fusion
BMEA
$84.6M
$1.7M 0.59%
798,757
– –
CALC icon
9
CalciMedica
CALC
$15.8M
$995K 0.35%
521,114
– –
ELEV
10
DELISTED
Elevation Oncology
ELEV
$735K 0.25%
2,834,910
– –
ACRS icon
11
Aclaris Therapeutics
ACRS
$726M
$665K 0.23%
434,455
– –
MRKR icon
12
Marker Therapeutics
MRKR
$18.8M
$400K 0.14%
325,370
– –
OKUR
13
OnKure Therapeutics
OKUR
$154M
$381K 0.13%
88,607
– –
VIRX
14
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
– –
-288,571
Closed -$46.2K
PSTX
15
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
– –
-1,043,267
Closed -$10M

Similar funds

BF
Brooklyn FI New York $476M AUM 17.97% 1-Year Est. Return
VIA
Vickerman Investment Advisors Spokane, Washington $476M AUM 12.21% 1-Year Est. Return
DE
Devon Energy Houston, Texas $476M AUM
FAM
Frontier Asset Management Sheridan, Wyoming $477M AUM 19.41% 1-Year Est. Return
BHWA
Beacon Harbor Wealth Advisors Virginia Beach, Virginia $477M AUM 49.25% 1-Year Est. Return
AL4A
Accel Leaders 4 Associates Palo Alto, California $475M AUM 391.52% 1-Year Est. Return
LEFP
Leading Edge Financial Planning Knoxville, Tennessee $475M AUM 15.22% 1-Year Est. Return
MVP
Medina Value Partners Los Angeles, California $477M AUM 25.52% 1-Year Est. Return

Aisling Capital Management's Q1 2025 Portfolio in Review

As of Q1 2025, Aisling Capital Management held 15 positions worth $288M, up 2.3% from $282M the previous quarter. Its ten largest holdings account for 99% of the portfolio.

Aisling Capital Management withdrew a net $39.1M in Q1 2025, closing 2 positions and reducing 1 holding. Its most notable exit was Poseida Therapeutics, Inc. Common Stock, an estimated $10M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Aisling Capital Management added an estimated $898K to Compass Pathways.

  • Aisling Capital Management added most to Compass Pathways in Q1 2025, an estimated $898K increase.
  • Aisling Capital Management's biggest Q1 2025 reduction was Verona Pharma, cutting an estimated $29.9M.
  • Aisling Capital Management fully exited Poseida Therapeutics, Inc. Common Stock in Q1 2025, selling an estimated $10M.
  • Aisling Capital Management's ten largest holdings make up 99% of its $288M portfolio in Q1 2025.
  • Aisling Capital Management opened 0 new positions and closed 2 in Q1 2025.
  • Aisling Capital Management's portfolio value rose 2.3% quarter-over-quarter to $288M.

Based on Aisling Capital Management's 13F filing for Q1 2025, filed 13 May 2025.